C-reactive protein polymorphisms and genetic susceptibility to ischemic stroke and hemorrhagic stroke in the Chinese Han population

Qi WANG¹,¹, Hu DING¹,¹, Jia-rong TANG¹,¹, Lan ZHANG¹, Yu-jun XU¹, Jiang-tao YAN¹, Wei WANG¹, Ru-tai HUI², Cong-qi WANG³, Dao-wen WANG¹,*

¹The Institute of Hypertension and Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030; ²Fuwai Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100037, China; ³Center for Biotechnology and Genomic Medicine, Medical College of Georgia, 1120 15th Street, CA4098, Augusta, GA, USA

Aim: The inflammatory marker C-reactive protein (CRP) has been strongly correlated with the risk of cardiovascular disease. Some single-nucleotide polymorphisms (SNPs) have been reported to be associated with serum CRP levels. In this study, we assessed the genetic association between SNPs within the CRP gene and ischemic and hemorrhagic stroke in the Han Chinese population.

Methods: This study comprises 564 ischemic stroke patients, 220 hemorrhagic stroke patients and 564 controls from the ethnic Han Chinese population in Wuhan. Four CRP SNPs, -757A>G (rs3093059), -717A>G (rs2794521), -286C>T>A (rs3091244) and +2147C>T (rs1205), were genotyped from patients using TaqMan assays.

Results: The A allele frequency for the -717A>G polymorphism was significant higher in controls than in ischemic stroke patients (P=0.037), after adjustment for traditional risk factors (odds ratio 0.28; 95% CI 0.12–0.65; P=0.003), suggesting a protective effect for this allele against ischemic stroke. Haplotype analysis showed that the H3 (G-C-C) haplotype conferred a significantly increased risk of ischemic stroke (odds ratio 1.052, 95% CI 1.001–1.106: P=0.047). Neither CRP genotypes nor haplotypes showed an association with hemorrhagic stroke. However, the frequency for haplotype H5 (A-T-C) was significantly higher in ischemic stroke than hemorrhagic stroke patients (P=0.0003).

Conclusions: These data suggest that the CRP gene -717A allele confers a protective effect against ischemic stroke. Furthermore, the H3 haplotype (G-C-C) is an independent risk marker for ischemic stroke, whereas the H5 haplotype (A-T-C) can be used as a prognostic marker of hemorrhagic stroke.

Keywords: C-reactive protein gene; stroke; genetic polymorphism
Acta Pharmacologica Sinica (2009) 30: 291–298; doi: 10.1038/aps.2009.14

Introduction

Stroke is a leading cause of death worldwide[1]. In China, the incidence of stroke is much higher than that of coronary heart disease compared with incidences recorded for Western countries[2]. Among all subtypes, ischemic stroke accounts for the majority of cases in the Chinese population, about 60%, and cerebral hemorrhage accounts for another 20%–40%[3]. In contrast, the overall incidence of stroke and the proportion of hemorrhagic strokes are lower in most Western countries than in China[3–6]. These different epidemiological patterns may be due to differences in genetic backgrounds of the populations.

Stroke is a heterogeneous multifactorial disorder. Acute cardiovascular events and stroke are thought to be caused largely by inflammation-mediated destabilization and rupture of atherosclerotic lesions[7,8]. Numerous classic risk factors such as hypertension, diabetes mellitus, hyperlipidemia and smoking contribute to this disease[9–12], but family and twin-based studies suggest the involvement of genetic factors in the development of stroke[13–15]. By case-controlled association studies, several inflammatory molecular genotypes...
have been suggested to be associated with increased stroke risk\textsuperscript{[16]}. C-reactive protein (CRP), an acute inflammatory phase reactant, is a marker of systemic inflammation\textsuperscript{[17]}. It has also evolved as a novel plasma marker for atherothrombotic disease and may reflect the level of inflammatory activity within atherosclerotic plaques\textsuperscript{[18–20]}. Therefore, CRP serum level is a valuable and sensitive indicator of initial and recurrent cerebrovascular events\textsuperscript{[21–23]}. Genetic variants in the CRP gene may more accurately reflect lifetime CRP exposure than serum CRP level measured at a single time point. Understanding of CRP genetic variation in stroke risk has been limited and controversial, especially for hemorrhagic strokes. Recently, a case-controlled study of a Japanese population suggested a strong association between CRP 1059G>C (rs1800947) polymorphism and ischemic stroke\textsuperscript{[24]}. On the contrary, no association was detected between this allele and ischemic stroke risk in a Swedish population\textsuperscript{[25]}. To address the role of CRP variability in stroke risk, we genotyped four CRP SNPs in the Han Chinese population. Our data support the association between CRP genetic variants and the risk of both ischemic and hemorrhagic stroke.

Materials and methods

**Study population and data collection** This multicenter study for the assessment of risk factors for stroke was sponsored by the Ministry of Science and Technology of China. The study protocol was approved by the review boards of the Ministry of Public Health, the Ministry of Science and Technology of China, and the ethics committees at all participating hospitals. Informed consent was obtained from all participants.

The study population was composed of 564 patients with ischemic stroke, 220 patients with primary cerebral hemorrhage, and 564 control subjects. All patients and control subjects were recruited from patients consecutively admitted to five hospitals in Wuhan, China, from November 2004 to June 2006. Diagnosis of stroke was based on medical history, neurological examination, and CT or MRI according to the International Classification of Diseases, ninth edition. Only patients with one of these three subtypes of stroke were included: cerebral thrombosis (atherothrombosis), lacunar infarction (lacunar), and intracerebral hemorrhage. Other types of stroke (including subarachnoid hemorrhage, cardiogenic embolic brain infarction, brain tumors and cerebrovascular malformations), severe systemic diseases (except diabetes mellitus), severe inflammatory diseases, autoimmune disease, tumors, and serious chronic diseases (eg, hepatic cirrhosis, renal failure) were excluded. Controls were randomly selected from inpatients with minor illnesses from the Departments of Ophthalmology, Gastroenterology, Otorhinolaryngology and Orthopedics, or were healthy individuals from the community. The exclusion criteria for control subjects were the same as those in the aforementioned patient group. Controls had no relationship with the stroke cases and no family history of stroke. All subjects were unrelated Han Chinese individuals originating from the same geographical area.

**Data collection and definition of risk factors** Information on demographics and other risk factors was collected by use of a structured questionnaire involving the history of hypertension, diabetes, hyperlipidemia, smoking, and physical exercise, including evaluation of body mass index.

Hypertension was defined as a systolic blood pressure ≥140 mmHg, a diastolic blood pressure ≥90 mmHg, or current treatment with an antihypertensive drug. Diabetes was diagnosed by a fasting glucose level of >7.8 mmol/L, or a glucose level of >11.1 mmol/L at 2 h after oral glucose challenge, or both. Hyperlipidemia was defined as total plasma cholesterol level of >5.72 mmol/L or plasma triglyceride >1.70 mmol/L. If a subject had smoked at least 1 cigarette per day for at least 1 year and had not quit smoking by the time of the study, he/she was defined a current smoker.

**Blood sample collection, biochemical variables and genomic DNA extraction** Blood was drawn from an arm vein into a sterile tube containing ethylenediamine tetraacetic acid (EDTA). Plasma samples were obtained from fasting participants and stored at -80 °C. Plasma biochemical parameters were assayed using an automatic analyzer (7060, Hitachi). Seven hundred and sixty-one subjects, including 431 subjects of ischemic strokes, 67 subjects of hemorrhagic strokes and 263 controls, were randomly selected for CRP level measurement. CRP level was measured with a Dade Behring BNII nephelometer. Genomic DNA was extracted using the QG-Mini80 workflow with DB-S kit (FUJIFILM Corporation, Tokyo, Japan) per the manufacturer’s instructions. DNA was diluted to a final concentration of 10 ng/µL and stored at -80 °C for genotyping.

**TagSNP selection and genotyping** Based on information in the NCBI SNP database and International HapMap project data (http://www.hapmap.org) for the Han Chinese population, SNPs with a minor allele frequency >10% and previously published SNPs were selected for the study\textsuperscript{[26, 27]}, including -757A>G (rs3093059), -717A>G (rs2794521), and -286C>T>A (rs3091244) located in the promoter region and +2147C>T (rs1205) in the 3′ flanking region.

TagSNPs were genotyped using the TaqMan SNP Geno-
Wang Q et al

The three diallelic SNPs were designed and supplied commercially by GeneCore Inc (GeneCore, Shanghai). The triallelic variant was supplied by Applied Biosystems Inc (ABI, Foster City, CA). The primer and probe sequences of these SNPs are listed in Table 1. Each probe was dually labeled with a reporter dye at the 5’ end and contained a minor groove-binding group (MGB) at the 3’ end.

The polymerase chain reactions for tagSNPs (-757A>G, -717A>G, +2147C>T) were carried out in 5 μL final volume and were composed of 1×Universal Mastermix (ABI), two TaqMan probes at 0.2 μmol/L each, two primers at 1 μmol/L each and 1 ng/μL genomic DNA. Thermal cycling reactions were performed as follows: 50 °C for 2 min, 95 °C for 10 min, and then 50 cycles at 95 °C for 15 s and 60 °C for 1 min. Amplifications were carried out on the ABI 7900HT instrument. Allelic discrimination was measured automatically using Sequence Detection Systems 2.1 software (autocaller confidence level 95%). Primers, TaqMan probes and PCR conditions used for genotyping and analysis of triallelic SNP (rs3091244) have been described previously by Carlson et al[28]. A total of 10% of samples were re-genotyped for each SNP at random, and all results were consistent. In addition, all DNA samples for cases and controls were blindly run in the same batches.

### Statistical analysis
Statistical analyses were performed with the SPSS 13.0 software package (SPSS Inc, Chicago) for Windows (Microsoft Corp, Redmond, Wash) and haplo.stats version 1.2.1 for the R programming language. Summary statistics were expressed as means±standard error (SEM) or as percentages, and CRP levels were expressed as medians. The χ² test was used to assess the deviation from Hardy-Weinberg equilibrium for genotype frequencies and to examine genotype and allele frequencies between cases and controls. Frequencies of categorical variables were compared by χ² test or Fisher’s exact test. Continuous variables were compared between cases of stroke and controls using Student’s t-test. CRP levels had a skewed distribution and nonparametric tests were used. The potential independent role of each SNP on stroke was investigated with multiple logistic regression analyses adjusted for age, sex, BMI, hypertension, hyperlipidemia, diabetes mellitus and smoking status. To avoid spurious allelic associations, a probability value <0.0125 (0.05/4) was considered statistically significant after Bonferroni correction was applied to conservatively identify the susceptibility variants on CRP. The association between CRP levels and CRP genotype was investigated with stepwise linear regression adjusted for the above-mentioned risk factors. CRP levels were natural log transformed in this model. The r² measurement was used to determine linkage disequilibrium (LD) with the software EMLD (http://request.mdacc.tmc.edu/qhuang/Software/pub.htm). The frequency distribution of haplotypes was calculated by the haplo.stats software. Haplotype-based hypothesis tests of generalized linear models were conducted using haplo.stats, in which ischemic or hemorrhagic stroke status was the dependent variable, and haplotypes and the other classic risk factors were independent and covariate variables[29].

The present study had 80% power to detect an association with OR <0.40 (assuming a protective effect) for alleles ≥15% frequency assuming a two-sided level at 0.05 using the QUANTO program in recessive model[30]. P<0.05 was considered statistically significant, and all statistical tests were two sided.

### Results

#### Characteristics of patients and control subjects
The baseline characteristics of all participants are summarized in Table 2. The mean age was older in the control subjects than in either ischemic or hemorrhagic stroke patients. As expected, the frequencies of hypertension, serum CRP levels, systolic blood pressure and diastolic blood pressure were

| Table 1. Sequences of TaqMan primers and probes. |
|-----------------------------------------------|
| Primer (5’→3’) | Probe |
|----------------|-------|
| rs3093059     | Forward TTTGGTGTITTTGATGGACACA | FAM-CTCACGCAATGTTACA-MGB |
|               | Reverse TGTACGGGCTAGCTATTTAGT    | TET-TCTAGCGCATTGAGTA-MGB |
| rs2794521     | Forward CCGTCATTAGTGCCAAAGATGT   | FAM-ACCAGCTGTITCTC-MGB |
|               | Reverse CTCCTGGTCACTCCATTTCTCAT  | TET-CACCGGTGTITCT-MGB |
| rs1205        | Forward GGTAGTCCACCTTCCCTTGT     | FAM-CTGTGACTTACAGTCT-MGB |
|               | Reverse ACCACCGTACGTCATTTCTT      | TET-TGACGGTACTTACAGTCT-MGB |
| rs3091244     | Forward TGTTGAGGAGGAGCTACCA       | NED-ATGGCCACTTATTTA-MGB |
|               | Reverse TCCTGGCAAAATATGGGAAA      | VIC-ATGGCCACTTATTTA-MGB |
|               |                                  | FAM-TGACCACCTTTAAA-MGB |
higher in stroke patients than in controls. The proportions of sex, smoking status, and total cholesterol level did not differ between stroke patients and controls. Body mass index and frequencies of diabetes mellitus and hyperlipidemia were higher in ischemic stroke patients than in controls; however, the frequency of hyperlipidemia was lower in hemorrhagic stroke patients. Body mass index and the frequency of diabetes mellitus did not differ between hemorrhagic stroke patients and controls.

**CRP genotypes in relation to ischemic stroke, hemorrhagic stroke and CRP level** All genotype distributions were consistent with the Hardy-Weinberg equilibrium except -757A>G, which was removed from further analysis. Genotype frequencies are shown in Table 3. No significant differences were observed in genotype distributions between hemorrhage patients and controls. However, the -717A>G genotype frequencies in the recessive model (AA+AG vs GG) differed significantly between ischemic stroke patients and controls (P=0.037). Furthermore, after adjustment for age, gender, BMI, and frequencies of hypertension, diabetes mellitus, hyperlipidemia and smoking, -717A>G was still associated with ischemic stroke (AA+AG vs GG, odds ratio 0.28; 95% CI 0.12–0.65; P=0.003, Table 4). Furthermore, this SNP was still significantly associated with ischemic stroke after a Bonferroni adjustment. Age (odds ratio 0.96; 95% CI 0.94–0.97; P<0.001), hypertension (odds ratio 11.46; 95% CI 8.36–15.71; P<0.001), and diabetes mellitus (odds ratio 3.77; 95% CI 2.11–6.73; P<0.001) were also estimated as independent predictors of ischemic stroke (Table 4). Nevertheless, there was no association between any genotype and serum CRP levels after adjustment for risk factors (Table 5).

**Haplotype analysis** Pairwise LD measures and correlation coefficients between CRP polymorphisms were analyzed. None of our tagSNPs were high in LD (r²≤0.30). We used haplo.stats software to calculate haplotypes based on the observed genotypes. To minimize potential false positive associations conducted in haplotype analysis, haplotypes were not considered if all estimated frequencies are less than 5% in controls and cases. No significant association was detected for any haplotype and ischemic stroke.

Next, we analyzed the independent effect of haplotype on ischemic stroke after adjustment for other risks. Haplotype H1 was the most frequent and was thus chosen as the baseline. As expected, haplotype H3 was associated with an increased risk of ischemic stroke (odds ratio 1.052, 95% CI 1.001–1.106: P=0.047; Table 6). Other risk factors that showed significant effects on ischemic stroke were also listed in Table 6. These results were consistent with logistic regression analysis. Haplotype H5 was significantly less frequent in hemorrhagic stroke patients than in controls (2.7% versus 5.5%, P=0.024; Table 7). In contrast, haplotype H3 was higher in hemorrhagic stroke patients, with marginal significance (14.7% versus 18.6%, P=0.054; Table 7). However, after the adjustment of conventional risk factors, haplotypes H3 and H5 failed to show a significant difference between controls and hemorrhagic stroke patients (P=0.075 and P=0.064, respectively; data not shown).

**Difference in allele frequencies and haplotype between ischemic stroke and hemorrhagic stroke** The allele frequencies did not differ significantly between ischemic stroke or hemorrhagic stroke and controls. However,
the frequency for -286T was significantly higher in ischemic than in hemorrhagic stroke patients, whereas -286A was higher in hemorrhagic stroke patients ($P = 0.027$, Table 8). In addition, the frequency for haplotype H5 (A-T-C) was significantly higher in ischemic stroke than hemorrhagic stroke (6.9% vs 2.7%, $P = 0.0003$, data not shown).

Table 3. Genotype distribution in patients with ischemic and hemorrhagic stroke and control subjects.

| SNP      | Genotype | Controls ($n=564$) | Ischemic stroke ($n=564$) | Hemorrhagic stroke ($n=220$) |
|----------|----------|--------------------|---------------------------|-------------------------------|
|          |          | n | n  | Crude $P$ value | Adjusted $P$ value | n  | n  | Crude $P$ value | Adjusted $P$ value |
| rs2794521 | Additive |   |   |                |                       |   |   |                |                       |
|          | AA       | 398 | 386 | 0.110 | 0.009$^b$ | 143 | 0.247 | 0.164 |
|          | AG       | 155 | 155 |       |            | 70  |    |            |                       |
|          | GG       | 11  | 23  |       |            | 7   |    |            |                       |
|          | Recessive |   |   |                |                       |   |   |                |                       |
|          | AA+AG    | 553 | 541 | 0.037$^b$ | 0.003$^b$ | 213 | 0.301 | 0.142 |
|          | GG       | 11  | 23  |       |            | 7   |    |            |                       |
|          | Dominant |   |   |                |                       |   |   |                |                       |
|          | AA       | 398 | 386 | 0.438 | 0.202    | 143 | 0.130 | 0.135 |
|          | GG+AG    | 166 | 178 |       |            | 77  |    |            |                       |
| rs3091244 | Additive |   |   |                |                       |   |   |                |                       |
|          | CC       | 323 | 340 | 0.125 | 0.262    | 137 | 0.358 | 0.357 |
|          | CA       | 157 | 134 |       |            | 57  |    |            |                       |
|          | CT       | 53  | 60  |       |            | 12  |    |            |                       |
|          | AA       | 19  | 15  |       |            | 11  |    |            |                       |
|          | TT       | 5   | 3   |       |            | 1   |    |            |                       |
|          | AT       | 7   | 12  |       |            | 2   |    |            |                       |
| rs1205   | Additive |   |   |                |                       |   |   |                |                       |
|          | TT       | 173 | 172 | 0.440 | 0.194    | 68  | 0.686 | 0.109 |
|          | TC       | 297 | 282 |       |            | 110 |    |            |                       |
|          | CC       | 94  | 110 |       |            | 42  |    |            |                       |
|          | Recessive |   |   |                |                       |   |   |                |                       |
|          | TT+TC    | 470 | 454 | 0.216 | 0.085    | 178 | 0.421 | 0.056 |
|          | CC       | 94  | 110 |       |            | 42  |    |            |                       |
|          | Dominant |   |   |                |                       |   |   |                |                       |
|          | TT       | 173 | 172 | 1.000 | 0.999    | 68  | 0.949 | 0.793 |
|          | TC+CC    | 391 | 392 |       |            | 152 |    |            |                       |

Crude $P$ values were determined by a 95% two-sided $\chi^2$ test. Adjusted $P$ value was calculated by multiple logistic regression analysis with adjustment for age, sex, BMI, history of hypertension, hyperlipidemia, diabetes mellitus and smoking. $^bP<0.05$ vs controls.

Table 4. Multivariate logistic regression analysis of determinants of ischemic stroke.

| Variable            | Adjusted OR | 95% CI | $P$ value |
|---------------------|-------------|--------|-----------|
| Age (year)          | 0.96        | 0.94–0.97 | <0.001$^b$ |
| Sex (M/F)           | 0.96        | 0.70–1.33 | 0.824     |
| BMI                 | 1.00        | 0.96–1.04 | 0.966     |
| Hypertension(y/n)   | 11.46       | 8.36–15.71 | <0.001$^b$ |
| Diabetes mellitus(y/n) | 3.77    | 2.11–6.73 | <0.001$^b$ |
| Hyperlipidemia (y/n) | 1.35     | 0.97–1.89 | 0.077     |
| Smoking (y/n)       | 0.81        | 0.57–1.16 | 0.253     |
| rs2794521, AA+AG vs GG | 0.28 | 0.12–0.65 | 0.003$^b$ |

Variables included in the model were sex, age, BMI, hypertension, hyperlipidemia, diabetes mellitus, and smoking. $^bP<0.05$ vs controls.

To our knowledge, this is the first study assessing the contribution of the $CRP$ gene to ischemic and hemorrhagic stroke in the Han Chinese population. We have shown here that the -717A>G polymorphism is not only associated with ischemic stroke, but also an independent predictor of ischemic stroke in this ethnic group.
-717A>G is located in the promoter region of the CRP gene. Our results suggested that -717A was a protective allele against ischemic stroke. Previous studies have indicated that the -717A allele is associated with increased risk for coronary heart disease and diabetes [27, 31], although contradictory results have also been reported [32]. Because stroke and coronary heart disease are both considered atherosclerosis-related diseases, they share a variety of common pathogenic mechanisms. This discrepancy could be due to a number of factors. First, -717A>G could be involved in the development of these two diseases by different mechanisms. The transition of -717A>G creates a potential binding site for glucocorticoid receptor (GR), which may result in changes in CRP expression. Consistent with this model, previous studies demonstrated that the -717G allele was associated with elevated CRP concentrations during the acute phase of stroke or transient ischemic attack [33]. Alternatively, population stratification caused by inappropriate sampling could be an influence. However, the allelic frequencies for the -717A>G polymorphism in ischemic stroke patients were actually quite similar to the previously published data [33], suggesting that the possibility of a false association was low. Finally, false positive results due to genotyping errors are

**Table 5.** Association of CRP genotype with plasma CPR level.

| SNP       | Genotype | CRP, mg/L Median (IQR-range) | Adjusted P value |
|-----------|----------|------------------------------|------------------|
| rs2794521 | AA       | 1.300 (0.464–3.630)         | 0.280            |
|           | AG       | 1.345 (0.525–4.122)         |                  |
|           | GG       | 1.362 (0.406–4.660)         |                  |
| rs30912244| AA       | 2.925 (0.656–5.733)         | 0.220            |
|           | AC       | 1.351 (0.530–4.595)         |                  |
|           | AT       | 2.650 (1.148–7.983)         |                  |
|           | CC       | 1.270 (0.422–3.400)         |                  |
|           | CT       | 1.420 (0.550–4.359)         |                  |
|           | TT       | 0.400 (0.230–3.477)         |                  |
| rs1205    | CC       | 1.420 (0.629–4.840)         | 0.444            |
|           | CT       | 1.318 (0.490–3.638)         |                  |
|           | TT       | 1.095 (0.390–3.370)         |                  |

Adjusted P value was calculated by stepwise linear regression analysis with adjustment for age, sex, BMI, history of hypertension, hyperlipidemia, diabetes mellitus, and smoking.

**Table 6.** Association between haplotype and ischemic stroke.

| Coefficient | Odds ratio | 95% CI | P value |
|-------------|------------|--------|---------|
| Age         | –0.007     | 0.993  | 0.990–0.995 | 8.9×10^-16 |
| Sex         | 0.003      | 1.003  | 0.948–1.061 | 0.917     |
| BMI         | –0.000     | 1.000  | 0.993–1.007 | 0.946     |
| Hypertension| 0.507      | 1.660  | 1.575–1.750 | 0.000b    |
| Diabetes mellitus | 0.184   | 1.202  | 1.106–0.977 | 1.7×10^-3b |
| Hyperlipidemia | 0.049   | 1.050  | 0.991–1.112 | 0.097     |
| Smoking     | 0.032      | 1.032  | 0.970–1.099 | 0.318     |
| H2 (A-A-C)  | –0.008     | 0.991  | 0.943–1.043 | 0.742     |
| H3 (G-C-C)  | 0.051      | 1.052  | 1.001–1.106 | 0.047b    |
| H4 (A-C-C)  | –0.015     | 0.985  | 0.915–1.061 | 0.692     |
| H5 (A-T-C)  | 0.006      | 1.006  | 0.935–1.082 | 0.873     |
| H1 (A-C-T)  | 1.000      |        |          |          |

Variables included in the model were sex, age, BMI, hypertension, hyperlipidemia, diabetes mellitus, and smoking. The H1 (A-C-T) haplotype was the reference group. *P<0.05 vs controls.*

**Table 7.** Haplotype frequency estimates.

| Haplotype | Allele (IQR-range) | Control Frequency | Ischemic stroke Frequency | Hemorrhagic stroke Frequency | P value |
|-----------|--------------------|-------------------|---------------------------|----------------------------|---------|
| H1        | A                  | 0.551             | 0.542                     | 0.542                      | 0.772   |
|           |         C          | T                 |                           |                            |         |
| H2        | A                  | 0.165             | 0.149                     | 0.250                      | 0.545   |
|           |         A          | C                 |                           |                            |         |
| H3        | G                  | 0.147             | 0.170                     | 0.131                      | 0.054   |
|           |         C          | C                 |                           |                            |         |
| H4        | A                  | 0.058             | 0.057                     | 0.876                      | 0.492   |
|           |         C          | C                 |                           |                            |         |
| H5        | A                  | 0.035             | 0.069                     | 0.210                      | 0.024b  |
|           |         T          | C                 |                           |                            |         |

Haplotypes were not listed if all the estimated frequencies were less than 5% in controls and stroke cases. *P<0.05 vs controls.*

**Table 8.** Allele frequency between ischemic stroke and hemorrhagic stroke.

| SNP       | Allele | Ischemic stroke/% | Hemorrhagic stroke/% | P value |
|-----------|--------|-------------------|----------------------|---------|
| rs2794521 | A      | 0.822             | 0.809                | 0.567   |
|           | G      | 0.178             | 0.191                |         |
| rs3091244 | A      | 0.156             | 0.184                | 0.027b  |
|           | C      | 0.775             | 0.780                |         |
|           | T      | 0.069             | 0.036                |         |
| rs1205    | C      | 0.445             | 0.441                | 0.883   |
|           | T      | 0.555             | 0.559                |         |

*P<0.05 ischemic stroke group vs hemorrhagic stroke group.*
also very unlikely. In our study, we used the TaqMan SNP Genotyping System, which has much higher specificity and accuracy than previously used approaches. We randomly re-genotyped about 10% of the samples and failed to identify any discrepancies in our results.

Haplotype analysis also identified a significant association between haplotype H3 and ischemic stroke. Compared with haplotype H1, haplotype H3 was an independent risk predictor of ischemic stroke. These two haplotypes differed only by the -717G and +2147C alleles. Previous studies have indicated that -717G and +2147C alleles are associated with high CRP levels\(^{33,34}\). Therefore, this may explain why the H3 haplotype is associated with increased risk of ischemic stroke. In addition, the haplotype containing the -717G allele showed this effect on ischemic stroke, consistent with our logistic regression analysis. In hemorrhagic stroke patients, the frequency of haplotype H5 was lower than that of controls. However, H5 was not an independent protective factor against hemorrhagic stroke, and previous studies indicated that the -286T and +2147C alleles were also associated with high CRP levels\(^{25,28,34,35}\). One possible explanation for this finding is that the SNPs of -286C>T>A and +2147C>T are markers of other confounding factors associated with low risk of hemorrhagic stroke.

Another interesting finding in our study is the significant difference in the triallelic SNP (-286C>T>A) frequency between ischemic and hemorrhagic stroke patients. This difference was mainly displayed in the distribution of minor alleles such as -286A or -286T. The ischemic group contained more -286T and less -286A, but the hemorrhage group was the opposite, with more -286A and less -286T. Recent functional analysis studies implicate the triallelic -286C>T>A promoter SNP as a functional variant, as the upstream stimulatory factor-1 can bind to it when the -286T is present\(^{25,36}\). Consistent with this, previous studies demonstrated that the -286T and -286A alleles were associated with higher plasma CRP levels\(^{25,34}\). To our knowledge, this is the first report showing genetic determinants for the distinction between ischemic and hemorrhagic stroke risk. However, because of the functional complexity in -286C>T>A SNP, the significance of differences in this allele frequency for the ischemic stroke and hemorrhagic stroke remains to be elucidated.

Our analysis failed to show an association between any SNP and serum CRP level in our study population, which is inconsistent with previous reports and our observations between genotyping and strokes. This may be due to a number of factors. On one hand, serum CRP levels can be affected by many conditions including infection, inflammatory events, smoking, diet and medications such as statins. These factors may disguise the association between serum CRP level and genotype. On the other hand, a previous report showed the association between -717A>G polymorphism and CRP levels only during acute stroke\(^{33}\), and some of our subjects blood samples were taken during the non-acute phase of the stroke.

In conclusion, potential associations between CRP gene polymorphisms and stroke risk were investigated in a Han Chinese population. We found that the -717A allele was significantly associated with lower risk for ischemic stroke and haplotype H3 (G-C-C) was an independent risk of ischemic stroke. No significant differences were observed in genotype distributions between hemorrhagic patients and controls. However, haplotype H5 (A-T-C) can be used as prognostic markers of hemorrhagic stroke.

Acknowledgements

This work was supported by grants from National “863” project (No 2006AA02A406) and “973” project (No 2007CB512004).

We thank Dr Tang-chun WU from the Institute of Occupational Medicine and Environment and Health, School of Public Health, Tongji Medical College for help in genetic statistics.

Author contribution

Qi WANG, Hu DING, and Dao-wen WANG designed this research; Qi WANG, Hu DING, Jia-rong TANG, Lan ZHANG, Yu-jun XU, and Jiang-tao YAN performed the research; Hu DING, Wei WANG, Ru-tai HUI, and Cong-yi WANG contributed new analytical tools and reagents; Qi WANG and Hu DING analyzed data; Qi WANG and Dao-wen WANG wrote the paper.

References

1. Bonow RO, Smaha LA, Smith SC Jr, Mensah GA, Lenfant C. World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 2002; 106: 1602–5.
2. Wu Z, Yao C, Zhao D, Wu G, Wang W, Liu J, et al. Sino-MONICA project: a collaborative study on trends and determinants in cardiovascular diseases in China, Part i: morbidity and mortality monitoring. Circulation 2001; 103: 462–8.
3. Jiang B, Wang WZ, Chen H, Hong Z, Yang QD, Wu SP, et al. Incidence and trends of stroke and its subtypes in China: results from three large cities. Stroke 2006; 37: 63–8.
4. Reed DM. The paradox of high risk of stroke in populations with
low risk of coronary heart disease. Am J Epidemiol 1990; 131: 579–88.
5. Zhang LF, Yang J, Hong Z, Yuan GG, Zhou BF, Zhao LC, et al. Proportion of different subtypes of stroke in China. Stroke 2003; 34: 2091–6.
6. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003; 2: 43–53.
7. Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med 1999; 340: 115–26.
8. Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 2006; 37: 1923–32.
9. Tanaka H, Ueda Y, Hayashi M, Date C, Baba T, Yamashita H, et al. Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community. Stroke 1982; 13: 62–73.
10. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035–8.
11. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350, 977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989; 320: 904–10.
12. Wolf PA, D’Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke. The Framingham Study. JAMA 1988; 259: 1025–9.
13. Tournier-Lasserve E. New players in the genetics of stroke. N Engl J Med 2002; 347: 1477–82.
14. Hassan A, Markus HS. Genetics and ischaemic stroke. Brain 2001; 124: 175–91.
15. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke, aetiology, risk factors, and public health burden. Lancet 2003; 362: 1306–15.
16. Selhub J, Jacques PF, Wilson PWF. Vitamin E and the prevention of Alzheimer’s disease. Arch Neurol 1998; 55: 892–6.
17. Ban et al. A C-reactive protein promoter polymorphism is associated with type 2 diabetes mellitus in Pima Indians. Mol Genet Metab 2003; 78: 136–44.
18. Wang Q et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 2006; 113: 1415–23.
19. Wang Q, Hunt SC, Xu Q, Chen YE, Province MA, Eckfeldt JH, et al. Association study of CRP gene polymorphisms with serum CRP levels and cardiovascular events. Eur J Epidemiol 2007; 22: 623–38.
20. Ben-Assayag E, Shenhar-Tsarfaty S, Bova I, Berliner S, Shopin L, Peretz H, et al. Triggered C-reactive protein (CRP) concentrations and the CRP gene -717A>G polymorphism in acute stroke or transient ischemic attack. Eur J Neurol 2007; 14: 315–20.
21. Kathiresan S, Larson MG, Vasan RS, Guo CY, Gona P, Keane JF Jr, et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 2006; 113: 1415–23.
22. Wang Q et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 2006; 113: 1415–23.
23. Wang Q et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 2006; 113: 1415–23.
24. Wang Q et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 2006; 113: 1415–23.
25. Wang Q et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 2006; 113: 1415–23.
26. Wang Q et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 2006; 113: 1415–23.
27. Wang Q et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 2006; 113: 1415–23.
28. Wang Q et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 2006; 113: 1415–23.
29. Wang Q et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 2006; 113: 1415–23.
30. Wang Q et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 2006; 113: 1415–23.
31. Wang Q et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 2006; 113: 1415–23.
32. Wang Q et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 2006; 113: 1415–23.
33. Wang Q et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 2006; 113: 1415–23.
34. Wang Q et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 2006; 113: 1415–23.
35. Wang Q et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 2006; 113: 1415–23.